Last reviewed · How we verify
HRZE
HRZE is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production.
HRZE is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production. Used for Tuberculosis (drug-susceptible, pulmonary and extrapulmonary).
At a glance
| Generic name | HRZE |
|---|---|
| Also known as | INH, RMP, PZA and EMB, isoniazid, H, rifampicin, R |
| Sponsor | Global Alliance for TB Drug Development |
| Drug class | Fixed-dose combination antituberculous agent |
| Target | Multiple: KatG/InhA (isoniazid), bacterial RNA polymerase (rifampicin), PncA/RpoB (pyrazinamide), arabinosyl transferase (ethambutol) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
HRZE combines isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), each targeting different aspects of Mycobacterium tuberculosis metabolism and cell wall integrity. Isoniazid inhibits mycolic acid synthesis, rifampicin blocks RNA polymerase, pyrazinamide disrupts energy metabolism in acidic environments, and ethambutol inhibits arabinosyl transferases. The combination provides rapid bactericidal activity and reduces the emergence of drug-resistant strains.
Approved indications
- Tuberculosis (drug-susceptible, pulmonary and extrapulmonary)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Hyperuricemia
- Optic neuritis (ethambutol-related)
- Rash
Key clinical trials
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
- Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis (PHASE2)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2, PHASE3)
- Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis (PHASE2)
- Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis (PHASE2)
- A Pan-TB Regimen Targeting Host and Microbe (PHASE2, PHASE3)
- A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide (PHASE2)
- Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |